CAPHRA calls for regulated access to e-cigarettes in Australia

Dec.16.2022
CAPHRA calls for regulated access to e-cigarettes in Australia
CAPHRA submits consultation document to TGA for access to legal electronic cigarettes and nicotine in Australia.

According to a submission by the Coalition of Asia Pacific Tobacco Harm Reduction Advocates (CAPHRA), just over 1% of people capable of writing nicotine scripts actually do so. Less than one-third of authorized prescribers are publicly available for adult smokers seeking to switch to nicotine e-cigarettes due to Australia's failed medicalized model.


CAPHRA has submitted a consultation paper to the Therapeutic Goods Administration (TGA) in Australia, discussing various options for legally obtaining electronic cigarettes and nicotine.


Australia remains the only Western democracy that requires a prescription for nicotine electronic cigarettes. The public consultation period regarding the proposed reform on the regulation of nicotine e-cigarette products in Australia began on November 30th and ended on January 16th, 2023.


Over the past decade, smoking rates in Australia have remained stable, particularly among vulnerable and disadvantaged communities. Nancy Loucas, the executive coordinator of CAPHRA, stated that "electronic cigarettes are one of the most effective methods for smokers worldwide to quit smoking, and access to them at retail outlets should have been restricted long ago.


CAPHRA stated that several countries, including the European Union, the United Kingdom, New Zealand, and Canada, are currently utilizing electronic cigarettes and reduced harm products to influence the rapid decline in smoking prevalence in these countries.


Ms. Lucas stated that the most deadly product to the public, combustible tobacco, is still readily available at any ordinary retailer, which is a mockery of public health.


Australia needs to determine whether their nicotine policy decisions are based on science, evidence, and facts to promote and maintain the health of their population, or if they choose money over health regarding tobacco consumption taxes and other possible funding they may receive due to their severe policy, which has proven to be a failure, according to CAPHRA.


Australian politicians and officials may not like to hear it, but if they want to see success, they need only cross the Tasman Sea. New Zealand has adopted an active harm reduction approach towards tobacco, and in the past decade, with the implementation of the Smokefree 2025 goal, their overall smoking rate has halved. Now they aim to achieve a regular smoking rate of only 5% or less. "Ms Loucas said.


Similarly, CAPHRA wrote that if youth access is truly a concern for Australian policymakers, the only solution is proper regulation and imposing strict fines and license revocations for non-compliant retailers. New Zealand's 2020 e-cigarette legislation and subsequent regulations achieved this.


According to Ms. Loucas, New Zealand has an effective consumer framework. In fact, in the past year alone, over 150,000 New Zealanders have switched from deadly combustible products to safer nicotine alternatives.


The Coalition of Asia Pacific Tobacco Harm Reduction Advocates (CAPHRA) believes that a regulated consumer market will enable Australia to have necessary control over the quality and quantity of products sold by community retailers. It also allows for products to be restricted to adults only – similar to alcohol and combustible cigarettes.


The report points out that there is currently a prevalence of unregulated black market products in Australia, with no regulatory control over their content or access for individuals under the age of 18.


We, on behalf of our nine member organizations, have submitted a letter of objection to the consultation document advocating for the 'gateway theory.' Despite the document's claim of evidence that electronic cigarettes lead to youth smoking, the gateway theory has been both confirmed and questioned by numerous international research institutions. Ms. Loucas stated that electronic cigarettes are an exit from smoking, not an entrance.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

JTI Liggett Puts U.S. Value Cigarette Brands in Spotlight at 2026 NACS Show
JTI Liggett Puts U.S. Value Cigarette Brands in Spotlight at 2026 NACS Show
At the 2026 NACS Show in Las Vegas, JTI Liggett highlighted its value-priced cigarette portfolio, including LD and Montego, following JT Group's acquisition of Vector Group. The company's U.S. business reported market share gains, with LD sales volume rising 32.6% in the first half of 2026. Meanwhile, Ploom was displayed separately at Altria's booth under an existing partnership. JTI Liggett booth staff told 2Firsts that the company had not yet launched nicotine pouch products in the United States.
EXPO
Oct.09
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane’s 2026 update of its living review on electronic cigarettes for smoking cessation included 80 randomized controlled trials involving 29,861 adult smokers, with nine trials added in this update. The review retained its high-certainty conclusion that nicotine e-cigarettes increase smoking cessation rates compared with nicotine replacement therapy. In absolute terms, about 10 in 100 people using nicotine e-cigarettes may quit smoking for at least six months, compared with about 6 in 100 using NRT. The review found no clear difference in serious adverse event rates between the two groups, while longer-term safety and the relative effectiveness of newer device types remain less certain.
Sep.07
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
Philip Morris International is expanding its U.S. ZYN nicotine pouch portfolio with new 1.5 mg and 8 mg strengths and plans to move its core 3 mg and 6 mg dry-pouch products from 15 to 20 pouches per can in the fourth quarter of 2026. ZYN ULTRA is also commercially available, with FDA authorization covering 10 products at 9 mg and one 11 mg Smooth product. PMI U.S. lists the new 1.5 mg and 8 mg strengths as commercially available, but as of September 10 they do not appear on the FDA’s public authorization list. Public materials do not identify which PMTA submissions cover the two new strengths or their current review status.
Sep.11
U.S. Customs Plan to Require Foreign Export Declarations Could Deal ‘Devastating’ Blow to China’s Vape Exports, Logistics gl Expert Says
U.S. Customs Plan to Require Foreign Export Declarations Could Deal ‘Devastating’ Blow to China’s Vape Exports, Logistics gl Expert Says
A U.S. Customs and Border Protection proposal to collect foreign export declarations and other overseas customs documents could expose discrepancies in the value, classification and description of China-made vape shipments entering the United States. A veteran Chinese logistics professional told 2Firsts that the measure, if implemented, could undermine the all-inclusive shipping model used by some unauthorized vape exporters and push parts of the trade toward costlier underground channels. The risk extends beyond higher duties: accurately declared products may also be more readily identified as unauthorized e-cigarettes subject to FDA enforcement.
Special Report
Sep.07
HG Innovation, linked to IMiracle and ELFBAR, wins China patent for 6-methylnicotine salts covering vaping and oral products
HG Innovation, linked to IMiracle and ELFBAR, wins China patent for 6-methylnicotine salts covering vaping and oral products
HG Innovation Limited has been granted a Chinese invention patent covering 6-methylnicotine salt formulations and their use in oral and vaping products. The technology forms salts between 6-methylnicotine and alicyclic carboxylic acids, with granted claims extending to oral products, atomization substrates and electronic atomization devices. Applicant-generated tests reported differences in oxidation stability, in-vitro cytotoxicity and aerosol heavy-metal performance compared with selected benzoate or lactate controls. HG Innovation is directly linked to the broader IMiracle and ELFBAR business network.
Sep.04
Product | JT Expands Vote-Winning EVO Cacao Mint Crystal to Nationwide Retail in Japan, Adds 22-Stick Limited Pack at Same Price
Product | JT Expands Vote-Winning EVO Cacao Mint Crystal to Nationwide Retail in Japan, Adds 22-Stick Limited Pack at Same Price
Japan Tobacco (JT) will expand EVO Cacao Mint Crystal from limited channels to nationwide retail in Japan from October 6, 2026. The Ploom tobacco stick ranked first in the brand's first consumer voting campaign for new tobacco-stick SKUs held earlier this year. JT will also introduce a limited 22-stick pack at the same JPY 620 price as the standard 20-stick pack. The capsule-format product combines menthol with sweet, bittersweet cacao notes and adds a berry nuance when the capsule is crushed.
Sep.09